Interview with Viktor Shafranskyi, General Manager, IPSEN Ukraine
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Address: 36 Pushkinskaya street, O1004, Kiev,Ukraine
Tel: 380445026529
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2010. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,500 employees.
Ipsen started its activities in Ukraine 20 years ago, with the promotion of a group of legacy products, the majority of which were dedicated to the treatment of gastrointestinal diseases. A couple of years later, Ipsen introduced its innovative franchise, whose three main therapeutic areas are in oncology, endocrinology, and for the treatment of neuro-muscular disorders. For the moment, the company’s strategic focus is to expand its innovative franchise and to push these medicines forward into the market.
Over the past seven years, the range of strategic products in Ipsen’s Ukraine portfolio has more than doubled. At the beginning of 2004, about 30% of sales came from the innovative franchise, whereas by the end of this year, around 60% of sales is expected to be generated by innovative medicines.
In both its targeted therapeutic areas and primary care, Ipsen has a diversified portfolio of leading drugs.
The Group’s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology, hematology), which are its primary areas of development. The Group also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular and cognitive disorders). To a large extent, these are composed of primary care.
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
You recently switched from Novartis to Unipharm. Given the major differences in environment and portfolio, what was it about Unipharm in particular that attracted you and what are you bringing…
Since 2006 Teva has been on a solid phase of growth and consolidation, mainly through the acquisitions of IVAX in 2006, Pliva (Barr) in 2008 and ratiopharm in 2010, which…
Following Takeda’s acquisition of Nycomed earlier this year, how has the transaction affected your operations in Ukraine and what synergies were generated by it? Regarding the integration process, we are…
As the founder of SMD what was it the prompted you to create this company and what were your objectives at that time? Up until 2003 when I created SMD,…
If you could provide our readers with your philosophy when you founded Sayenko Kharenko in 2004. What were the market needs that were perhaps missing that you identified and wanted…
It has been one year since you were appointed as the head of UCB’s operations in Ukraine. What was the mission of your assignment when you took this position and…
Considering you only took over as CEO from your father in 2009, what was the mandate that was given to you as new CEO of the company – including your…
Orion’s global strategy focuses on the CIS and Eastern European markets that still exhibit large growth potential and are expanding, despite a reverse trend for the rest of the industry.…
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi…
See our Cookie Privacy Policy Here
